By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
latest_posts
- 1
Jillian Michaels put me at the center of a body positivity debate. She's not entirely wrong about obesity. - 2Instructions to Shield Your Gold Speculation from Possible Dangers: Fundamental Protections
- 3WATCH: IDF strikes, dismantles missile launchers in southern Lebanon
- 4Council removes proposal to rename park named after former president of Israel
- 5Top 20 Wellbeing and Wellness Applications for a Sound Way of life
- Figure out How to Adjust Work, Life, and an Internet based Degree
- I decided to become a single mother by choice. I wasn't ready to stop dating.
- This Asian country is the next hot travel destination, and this is one of its best hotels
- Productive CRM Programming for Client Relationship The executives
- Volcanic eruption led to the Black Death, new research suggests
- Novo Nordisk cuts Wegovy price in South Africa for a second time
- New study measures titanium in Apollo rock to uncover Moon’s early chemistry
- Spain and Catholic Church agree to compensate sex abuse victims
- 5 Must-Attempt Fascinating Dishes from Around the World
